Dr. Brian T. Pruitt
Claim this profileThe Don and Sybil Harrington Cancer Center
Studies Breast Cancer
Studies Cancer
2 reported clinical trials
4 drugs studied
Area of expertise
1Breast Cancer
HER2 positive
ER positive
ER negative
2Cancer
HER2 positive
ER positive
ER negative
Affiliated Hospitals
Clinical Trials Brian T. Pruitt is currently running
Radiation Therapy + Olaparib
for Breast Cancer
This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.
Recruiting1 award Phase 248 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
More about Brian T. Pruitt
Clinical Trial Related5 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Brian T. Pruitt has experience with
- Trastuzumab Emtansine
- Tucatinib
- Olaparib
- Radiation Therapy
Breakdown of trials Brian T. Pruitt has run
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brian T. Pruitt specialize in?
Brian T. Pruitt focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Brian T. Pruitt currently recruiting for clinical trials?
Yes, Brian T. Pruitt is currently recruiting for 2 clinical trials in Amarillo Texas. If you're interested in participating, you should apply.
Are there any treatments that Brian T. Pruitt has studied deeply?
Yes, Brian T. Pruitt has studied treatments such as Trastuzumab Emtansine, Tucatinib, Olaparib.
What is the best way to schedule an appointment with Brian T. Pruitt?
Apply for one of the trials that Brian T. Pruitt is conducting.
What is the office address of Brian T. Pruitt?
The office of Brian T. Pruitt is located at: The Don and Sybil Harrington Cancer Center, Amarillo, Texas 79106 United States. This is the address for their practice at the The Don and Sybil Harrington Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.